2.75 USD
▲-0.02+5.36%
盘后 2.90 +11.11%
2026-08-03
市值
$35.09M
市盈率
—
EPS
-1.45
股息率
—
52 周区间
1.11 – 5.74
成交量
82.93K
Beta
2.33
目标价
20.00
52W 低 1.1152W 高 5.74
价格走势
公司简介
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in...